|Bid||6.00 x 1100|
|Ask||6.08 x 1400|
|Day's Range||5.99 - 6.25|
|52 Week Range||4.00 - 24.00|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2022 - Nov 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that Paul Kayne, Ph.D., Vice President of Biological Sciences at Palatin, presented today at the Eyecelerator@AAO in Chicago, IL. The presentation was one of several in the "Eyecelerator@ AAO 2022 - Therapeutics Showcase" general session.
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the Company will participate in the Ladenburg Thalmann Healthcare Conference on September 29, 2022.
Q4 2022 Palatin Technologies Inc Earnings Call